Literature DB >> 31190621

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Jacqueline M Dempsey1, Kelley M Kidwell2, Christina L Gersch3, Andrea M Pesch3, Zeruesenay Desta4, Anna Maria Storniolo4, Vered Stearns5, Todd C Skaar4, Daniel F Hayes3, N Lynn Henry3, James M Rae3, Daniel L Hertz1.   

Abstract

Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1*5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations.
Results: SLCO1B1*5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment.
Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

Entities:  

Keywords:  ; breast cancer; exemestane; letrozole; pharmacogenomics

Mesh：

Substances：

Year:  2019        PMID： 31190621      PMCID： PMC6891932          DOI： 10.2217/pgs-2019-0020

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  32 in total

1.  Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.

Authors:  James N Ingle; Aman U Buzdar; Daniel J Schaid; Matthew P Goetz; Anthony Batzler; Mark E Robson; Donald W Northfelt; Janet E Olson; Edith A Perez; Zeruesenay Desta; Randy A Weintraub; Clark V Williard; David A Flockhart; Richard M Weinshilboum
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

2.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

Authors:  Jürgen Geisler; Ben Haynes; Gun Anker; Mitch Dowsett; Per Eystein Lønning
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.

Authors:  Adrienne E Borrie; Rhiannon V Rose; Yun-Hee Choi; Francisco E Perera; Nancy Read; Tracy Sexton; Michael Lock; Theodore A Vandenberg; Karin Hahn; Robert Dinniwell; Jawaid Younus; Diane Logan; Kylea Potvin; Brian Yaremko; Edward Yu; John Lenehan; Stephen Welch; Rachel F Tyndale; Wendy A Teft; Richard B Kim
Journal:  Breast Cancer Res Treat       Date:  2018-08-09       Impact factor: 4.872

4.  Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

Authors:  Z Desta; Y Kreutz; A T Nguyen; L Li; T Skaar; L K Kamdem; N L Henry; D F Hayes; A M Storniolo; V Stearns; E Hoffmann; R F Tyndale; D A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2011-10-05       Impact factor: 6.875

5.  Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Authors:  Kunal C Kadakia; Kelley M Kidwell; Nicholas J Seewald; Claire F Snyder; Anna Maria Storniolo; Julie L Otte; David A Flockhart; Daniel F Hayes; Vered Stearns; N Lynn Henry
Journal:  Breast Cancer Res Treat       Date:  2017-04-27       Impact factor: 4.872

6.  Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.

Authors:  B J Gregory; S M Chen; M A Murphy; D H Atchley; L K Kamdem
Journal:  J Clin Pharm Ther       Date:  2017-07-29       Impact factor: 2.512

Review 7.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

8.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2015-07-23       Impact factor: 79.321

9.  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.

Authors:  N Lynn Henry; Jon T Giles; Dennis Ang; Monika Mohan; Dina Dadabhoy; Jason Robarge; Jill Hayden; Suzanne Lemler; Karineh Shahverdi; Penny Powers; Lang Li; David Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo; Daniel J Clauw
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

Review 10.  The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

Authors:  P E Lønning
Journal:  Ann Oncol       Date:  2010-07-08       Impact factor: 32.976
View more
  2 in total

Review 1.  Genetic Influences in Breast Cancer Drug Resistance.

Authors:  Adhitiya Daniyal; Ivana Santoso; Nadira Hasna Putri Gunawan; Melisa Intan Barliana; Rizky Abdulah
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-09

2.  Development and Validation of an ADME-Related Gene Signature for Survival, Treatment Outcome and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma.

Authors:  Xinran Tang; Rui Li; Dehua Wu; Yikai Wang; Fang Zhao; Ruxue Lv; Xin Wen
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.